Total Payments
$10,269
2023 Payments
$1,031
Companies
16
Transactions
31
Medicare Patients
21,517
Medicare Billing
$7.8M
Payment Breakdown by Category
Research$5,700 (55.5%)
Consulting$4,093 (39.9%)
Food & Beverage$258.77 (2.5%)
Education$185.44 (1.8%)
Other$31.25 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5,700 | 9 | 55.5% |
| Consulting Fee | $4,093 | 4 | 39.9% |
| Food and Beverage | $258.77 | 10 | 2.5% |
| Education | $185.44 | 7 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31.25 | 1 | 0.3% |
Payments by Type
Research
$5,700
9 transactions
General
$4,569
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $5,700 | 9 | $0 (2022) |
| GENZYME CORPORATION | $2,060 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $1,139 | 3 | $0 (2020) |
| Amgen Inc. | $1,031 | 2 | $0 (2023) |
| Incyte Corporation | $99.95 | 1 | $0 (2021) |
| PFIZER INC. | $54.15 | 3 | $0 (2019) |
| Daiichi Sankyo Inc. | $35.99 | 1 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.93 | 1 | $0 (2018) |
| Ipsen Biopharmaceuticals, Inc | $20.74 | 2 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $20.71 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,031 | 2 | Amgen Inc. ($1,031) |
| 2022 | $7,652 | 10 | Janssen Scientific Affairs, LLC ($5,700) |
| 2021 | $220.02 | 3 | GENZYME CORPORATION ($108.15) |
| 2020 | $1,171 | 4 | AstraZeneca Pharmaceuticals LP ($1,124) |
| 2019 | $59.42 | 4 | Novartis Pharmaceuticals Corporation ($20.71) |
| 2018 | $102.42 | 5 | PFIZER INC. ($31.25) |
| 2017 | $32.14 | 3 | Ipsen Biopharmaceuticals, Inc ($20.74) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/14/2023 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $187.50 | General |
| 03/27/2023 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $843.75 | General |
| 12/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $100.00 | Research |
| Study: MYLUNG | ||||||
| 10/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $900.00 | Research |
| Study: MYLUNG | ||||||
| 10/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $900.00 | Research |
| Study: MYLUNG | ||||||
| 10/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $100.00 | Research |
| Study: MYLUNG | ||||||
| 09/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $900.00 | Research |
| Study: MYLUNG | ||||||
| 09/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $900.00 | Research |
| Study: MYLUNG | ||||||
| 09/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $100.00 | Research |
| Study: MYLUNG | ||||||
| 08/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $900.00 | Research |
| Study: MYLUNG | ||||||
| 08/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $900.00 | Research |
| Study: MYLUNG | ||||||
| 07/20/2022 | GENZYME CORPORATION | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,952.00 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/25/2021 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $108.15 | General |
| Category: Oncology | ||||||
| 03/15/2021 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.95 | General |
| 07/24/2020 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $11.08 | General |
| Category: Oncology | ||||||
| 06/25/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Oncology | ||||||
| 06/15/2020 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $35.99 | General |
| Category: Oncology | ||||||
| 05/05/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Oncology | ||||||
| 09/10/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2019 | Novartis Pharmaceuticals Corporation | SANDOSTATIN (Drug) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: Oncology | ||||||
| 04/02/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/17/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Oncology | ||||||
| 06/30/2018 | PFIZER INC. | BOSULIF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $31.25 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MYLUNG | Janssen Scientific Affairs, LLC | $5,700 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 62 | 3,471 | 80,833 | $6.9M | $1.6M |
| 2022 | 56 | 3,147 | 51,109 | $3.0M | $600,859 |
| 2021 | 84 | 7,123 | 138,376 | $8.3M | $2.0M |
| 2020 | 96 | 7,776 | 290,721 | $15.5M | $3.6M |
Total Patients
21,517
Total Services
561,039
Medicare Billing
$7.8M
Procedure Codes
298
All Medicare Procedures & Services
298 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 29 | 19,400 | $2.9M | $812,697 | 28.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 20 | 20,640 | $1.7M | $488,329 | 29.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 3,900 | $271,740 | $71,396 | 26.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 140 | 331 | $276,210 | $32,988 | 11.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 235 | 396 | $71,584 | $26,444 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 166 | 273 | $82,402 | $25,909 | 31.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 15 | 10,300 | $216,300 | $24,382 | 11.3% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 14 | 252 | $221,508 | $23,293 | 10.5% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 12 | 180 | $259,920 | $13,662 | 5.3% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 28 | 5,330 | $47,970 | $7,371 | 15.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 254 | 716 | $44,392 | $7,363 | 16.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 292 | 872 | $30,520 | $6,595 | 21.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 52 | 52 | $23,952 | $6,304 | 26.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 59 | 127 | $51,704 | $6,247 | 12.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 42 | $15,901 | $5,378 | 33.8% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 98 | 130 | $13,260 | $5,156 | 38.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 97 | 436 | $45,780 | $5,110 | 11.2% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 17 | 74 | $5,180 | $5,106 | 98.6% |
| J1750 | Injection, iron dextran, 50 mg | Office | 2023 | 12 | 356 | $27,729 | $4,380 | 15.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $13,340 | $3,813 | 28.6% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 72 | 390 | $21,060 | $3,554 | 16.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 181 | 390 | $7,410 | $3,276 | 44.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 40 | 67 | $20,368 | $3,152 | 15.5% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 58 | 187 | $14,586 | $3,017 | 20.7% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 50 | 172 | $31,132 | $2,911 | 9.4% |
About Dr. John Paschold, MD
Dr. John Paschold, MD is a Specialist healthcare provider based in Williamsburg, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1962407510.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Paschold, MD has received a total of $10,269 in payments from pharmaceutical and medical device companies, with $1,031 received in 2023. These payments were reported across 31 transactions from 16 companies. The most common payment nature is "" ($5,700).
As a Medicare-enrolled provider, Paschold has provided services to 21,517 Medicare beneficiaries, totaling 561,039 services with total Medicare billing of $7.8M. Data is available for 4 years (2020–2023), covering 298 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Williamsburg, VA
- Active Since 06/20/2005
- Last Updated 11/29/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1962407510
Products in Payments
- LIBTAYO (Biological) $1,952
- IMFINZI (Drug) $1,110
- SARCLISA (Biological) $108.15
- Enhertu (Drug) $35.99
- BOSULIF (Drug) $31.25
- CALQUENCE (Drug) $29.36
- Onivyde (Drug) $20.74
- SANDOSTATIN (Drug) $20.71
- SYNDROS (Drug) $14.80
- ALIMTA (Drug) $14.42
- XARELTO (Drug) $12.79
- XTANDI (Drug) $11.50
- Xermelo (Drug) $11.47
- SUTENT (Drug) $11.40
- Imbruvica (Drug) $11.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Williamsburg
Dr. Carolyn Fleming Fruci, M.d, M.D
Specialist — Payments: $5,483
Specialist $5,483
Dr. Donna Corvette, M.d, M.D
Specialist — Payments: $904.82
Specialist $904.82
Keith Schumann, M.d, M.D
Specialist — Payments: $477.79
Specialist $477.79
Dr. Jeffrey Weidig, M.d, M.D
Specialist — Payments: $459.30
Specialist $459.30
Robert Soares
Specialist — Payments: $134.64
Specialist $134.64
Troy Thompson, M.d, M.D
Specialist — Payments: $47.06
Specialist $47.06